Reversible hepatotoxicity of paroxetine in a patient with major depression

C. Helmchen*, R. J. Boerner, R. Meyendorf, U. Hegerl

*Corresponding author for this work
25 Citations (Scopus)


Selective serotonin reuptake inhibitors (SSRIs) are becoming widely used because of their favorable side-effect profile and their safety in overdose. We report about a patient with recurring major depression (DSM-IIIR) who was treated with paroxetine and developed a severe hepatotoxic reaction, which was reversed after withdrawal of the drug. Individual, patient-related causes for this side-effect were not found. To our knowledge, this is the first published case of a probably paroxetine-induced severe hepatotoxicity. Hepatotoxicity should be taken into account as a rare complication that may occur not only with tricyclic antidepressants (TCAs) but also with SSRIs.

Original languageEnglish
Issue number6
Pages (from-to)223-226
Number of pages4
Publication statusPublished - 01.01.1996

Research Areas and Centers

  • Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)


Dive into the research topics of 'Reversible hepatotoxicity of paroxetine in a patient with major depression'. Together they form a unique fingerprint.

Cite this